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Abstract
Background: HIV-1 entry into cells is a multifaceted process involving target cell CD4 and the
chemokine receptors, CXCR4 or CCR5. The lipid composition of the host cell plays a significant
role in the HIV fusion process as it orchestrates the appropriate disposition of CD4 and co-
receptors required for HIV-1 envelope glycoprotein (Env)-mediated fusion. The cell membrane is
primarily composed of sphingolipids and cholesterol. The effects of lipid modulation on CD4
disposition in the membrane and their role in HIV-1 entry have extensively been studied. To focus
on the role of lipid composition on chemokine receptor function, we have by-passed the CD4
requirement for HIV-1 Env-mediated fusion by using a CD4-independent strain of HIV-1 Env.
Results: Cell fusion mediated by a CD4-independent strain of HIV-1 Env was monitored by
observing dye transfer between Env-expressing cells and NIH3T3 cells bearing CXCR4 or CCR5
in the presence or absence of CD4. Chemokine receptor signaling was assessed by monitoring
changes in intracellular [Ca2+] mobilization induced by CCR5 or CXCR4 ligand. To modulate target
membrane cholesterol or sphingolipids we used Methyl-β-cyclodextrin (MβCD) or 1-phenyl-2-
hexadecanoylamino-3-morpholino-1-propanol (PPMP), respectively. Treatment of the target cells
with these agents did not change the levels of CD4 or CXCR4, but reduced levels of CCR5 on the
cell surface. Chemokine receptor signalling was inhibited by cholesterol removal but not by
treatment with PPMP. HIV-1 Env mediated fusion was inhibited by >50% by cholesterol removal.
Overall, PPMP treatment appeared to slow down the rates of CD4-independent HIV-1 Env-
mediated Fusion. However, in the case of CXCR4-dependent fusion, the differences between
untreated and PPMP-treated cells did not appear to be significant.
Conclusion: Although modulation of cholesterol and sphingolipids has similar effects on CD4 -
dependent HIV-1 Env-mediated fusion, sphingolipid modulation had little effect on CD4-
independent HIV-1 Env-mediated fusion. Chemokine receptor function remained intact following
treatment of cells with PPMP. Therefore such treatment may be considered a more suitable agent
to inhibit CD4 dependent HIV-1 infection.
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Background
HIV-1 delivers its genetic material into the cell by direct
fusion of the viral membrane with the plasma membrane
of the host cells [1]. HIV-1 Env encodes a polypeptide
(gp160) that is folded in the endoplasmic reticulum into
a complex, disulphide-linked structure, which is anchored
in the membrane by virtue of the hydrophobic, mem-
brane-spanning domain in the gp41 moiety[2]. During
post-translational processing, the precursor glycoproteins
oligomerize and are extensively glycosylated before cellu-
lar proteinases cleave the precursor at a characteristic
sequence to create the mature glycoproteins gp120 and
gp41[3]. The surface glycoprotein, gp120, forms trimeric
spikes[4], which are associated by non-covalent interac-
tions with each subunit of the membrane-anchored
gp41[5].
The triggering mechanisms that activate Env are quite
complex involving target cell CD4 [6] and chemokine
receptors CCR5 and CXCR4 [7]. The current data support
a two-step model for receptor engagement that involves
initial interactions between gp120 and CD4, followed by
conformational changes in Env, which permit interaction
of the gp120-CD4 complex with co-receptor leading to a
further barrage of conformational changes that eventually
lead to gp41 6-helix bundle formation and fusion [1].
Receptors in membranes are not randomly distributed
and lipids can play an important role in choreography of
receptors [8]. Therefore it stands to reason that modula-
tion of lipid composition may affect the HIV-1 Env-medi-
ated fusion reaction by altering the two-step
choreography of CD4 and chemokine receptors required
for HIV-1 entry. Based on this hypothesis a plethora of
publications have appeared indicating that lipid modula-
tion may have an indirect effect on HIV-1 entry/fusion by
interfering with the choreography of CD4 and co-recep-
tors (for reviews see [9,10].
In order to further examine the effect of lipids on HIV-1
entry we asked the question whether similar lipid modu-
lation would affect HIV-1 entry/fusion when we consider
just one receptor required for entry. We addressed these
issues by performing studies with CD4-independent HIV-
1 Envs whose chemokine receptor-binding site is exposed
without prior interaction with CD4. Hoxie and coworkers
derived a variant of HIV-1/IIIB, termed 8x, which acquired
the ability to utilize CXCR4 without CD4 [11]. Moreover,
when the V3 loop of a CCR5-tropic Env was substituted
for its counterpart in the 8x Env, the resulting chimera
(8xV3BAL) was found to utilize CCR5 but remained CD4
independent [11]. We have used these constructs to fur-
ther explore the role of target membrane cholesterol and
glycosphingolipids in HIV-1 Env-mediated fusion.
Results
Removal of cholesterol
To remove cholesterol from cells, we used the cholesterol-
solubilizing agent methyl-β-cyclodextrin (MβCD), which
stimulates cholesterol efflux from cells [12]. Figure 1
shows that incubation of NIH3T3 cells with 10 mM
MβCD for 30 min at 37°C reduced cholesterol levels of
the cells to about 22% of untreated controls. There was no
significant effect on cell viability (not shown) or surface
expression of CD4 and coreceptors [13]. Figure 2 shows
that fusion mediated by CD4-independent HIV-1 Env was
reduced to about 30% of untreated controls for both 8x
and 8xV3BAL Envs, irrespective of the presence of CD4 in
the target membrane. When these cells were replenished
with cholesterol by incubation with pre-formed choles-
terol- MβCD complexes, HIV-1 env-mediated fusion was
fully recovered. Interestingly, in spite of the fact that cho-
lesterol levels were only replenished to 50% of untreated
control (Figure 1), HIV-1 Env-mediated fusion was fully
recovered (Figure 2). This observation is consistent with
the notion that the dependence of membrane organiza-
tion on cholesterol is not linear, but rather that there is a
critical concentration of cholesterol below which phase
separation of domains occurs [14].
Modulation of sphingolipid metabolism
To modulate shingolipid metabolism, we used an inhibi-
tor of GlcCer synthase, PPMP [15]. The effects of such
treatment was monitored by observing changes in the
expression of cell surface glycosphingolipids by flow
cytometry following the staining of the cells with anti-gly-
cosphingolipid antibodies [16]. In accordance with previ-
ous studies we observed a 4–5 reduction in GM3 levels
following treatment of the cells with 10 μM PPMP for 48
h (data not shown). Phospholipid and cholesterol com-
Cholesterol Levels in NIH3T3 cells after MβCD treatment Figure 1
Cholesterol Levels in NIH3T3 cells after MβCD 
treatment. NIH 3T3 cells were treated with 10 mM MβCD 
for 30 minutes at 37°C and cholesterol in total cell lysate was 
determined as described previously [13]. For the put-back 
experiments the cholesterol-depleted cells were incubated 
with an MβCD-cholesterol mixture for 60 minutes at 37°C 
according to [13].
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position of the cells were unchanged following PPMP
treatment as shown by our previously studies [17]. Figure
3 shows the cell surface expression levels of CD4, CXCR4
and CCR5 on control and PPMP treated cells. Although
there was no significant change in cell surface expression
of CD4 or CXCR4, the level of CCR5 expression was
reduced by about 50% following treatment of these cells
with PPMP consistent with our previous findings [17].
Effects of PPMP treatment on HIV-1 Env-mediated fusion
Cells expressing the 8x and 8xV3BAL variants of HIV-1IIIB
were incubated at different times with NIH3T3 cells bear-
ing CXCR4 and CCR5, respectively, with or without CD4.
Fusion was monitored before and after treatment of the
cells with PPMP. Although the Env constructs we used did
not require CD4 for fusion activity it appeared that, in the
case of the CXCR4 construct, presence of CD4 on the tar-
get cells enhanced the fusion reaction (Figure 4), presum-
ably as a result of better attachment or more robust
conformational changes, In the case of the CCR5 con-
struct, presence of CD4 on the target cell did not speed up
the fusion reaction significantly (Figure 5). However,
there was a significant difference in fusion mediated by
the CCR5 construct at the different time points between
untreated and PPMP-treated target cells (Figure 5) as indi-
cated by the p values determined by paired student t tests.
However, this reduction in fusion activity can be
explained by the reduced levels of cell surface CCR5 (Fig-
ure 3). PPMP did not have a significant effect on fusion
mediated by the CD4-independent CXCR4 construct as
indicated by the p values determined by paired student t
tests (Figure 4). Collectively, these data indicate that
PPMP-treatment does not affect the one-step fusion path-
way mediated by HIV-1 Env.
Effects of cholesterol and PPMP treatment on chemokine 
receptor function
Nguyen and coworkers showed that removal of choles-
terol from the cell membrane results in loss in ligand
binding which is likely due to conformational changes in
CXCR4 [18] or CCR5 [19]. In accordance with those
results, Figure 6 shows that Ca2+ mobilization in NIH3T3
cell lines expressing CXCR4 or CCR5 in response SDF-1α
or MIP-1β, respectively, was inhibited following treat-
ment of the cells with MβCD. If treatment of these cell
lines with PPMP has a similar effect on ligand binding, we
would expect Ca2+  mobilization in NIH3T3 cell lines
expressing CXCR4 or CCR5 in response SDF-1α or MIP-
1β, respectively, to be inhibited following treatment with
PPMP. By contrast, treatment of these cells with PPMP
had no effect on chemokine receptor signalling (Figure 6).
Thus, the cholesterol effect can be explained by changes in
chemokine receptor disposition that leads to engagement
with HIV-1 Env.
Discussion
The two-step model for HIV-1 Env-mediated fusion [1]
led to the notion that it is possible to interfere with the
two receptor choreography by re-arranging the dance
floor. The notion that cholesterol plays a key role in the
maintenance of membrane organization [20] has led to a
plethora of studies on the role of cholesterol in HIV-1
entry [10,13,18,21-31]. It has been hypothesized that
lipid raft domains [12] serve as sites that facilitate receptor
interactions and signalling processes, and promote the
cooperative event of HIV fusion. However, a role for rafts
in HIV-1 entry has been called in question since CD4
mutants that localize this HIV-1 receptor to non-raft
domains are perfectly capable of supporting HIV-1 entry
[26,27]. In this study we show that removal of cholesterol
leads to inhibition of the one-step mode of HIV-1 Env
fusion mediated by a CD4-independent strain of HIV-1
(Figure 2). The crucial step is the attachment of HIV-1
gp120 with CXCR4 or CCR5 inducing a barrage of confor-
mational changes in HIV-1 Env, which leads to HIV-1
gp41 six helix bundle formation and fusion. Nguyen and
co-workers have shown that maintenance of proper levels
of cholesterol in the membrane is essential for chemokine
binding and the conformational integrity of CCR5 [19] as
well as CXCR4 [18]. Our data on the effects of cholesterol
removal on signalling of CCR5 and CXCR4 (Figure 6) are
consistent with those results. Therefore, the most straight-
The effect of cholesterol depletion from NIH3T3 Targets on  CD4-independent HIV-1 Env-mediated fusion Figure 2
The effect of cholesterol depletion from NIH3T3 
Targets on CD4-independent HIV-1 Env-mediated 
fusion. CMFDA-labeled cells (2 × 105 per well) expressing 
HIV-18x (black and light gray bars) or HIV-18xV3BAL (dark gray 
and white bars) Envs were added to the CMTMR-labeled tar-
gets expressing cognate co-receptors. The samples were 
incubated for 6 hrs at 37°C before, after and following cho-
lesterol put-back as described in the legends to Figure 1. 
Fusion was determined as described in materials and meth-
ods.
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forward explanation for our data showing inhibition of
CD4-independent HIV-1 Env mediated fusion by choles-
terol removal is that the conformational integrity of CCR5
and CXCR4 is impaired by this treatment. Therefore, their
efficiency in grabbing HIV-1 gp120 and inducing the bar-
rage of conformational changes in HIV-1 Env necessary
for fusion has severely been reduced.
The situation with PPMP [15], which inhibits the synthe-
sis of GlcCer, the precursor for glycosphingolipids synthe-
sis, is somewhat more complex. Our initial hypothesis
was that glycosphingolipids play a role in HIV-1 entry/
fusion. Therefore, a reduction of glycosphingolipid levels
by blocking their synthesis would adversely affect HIV-1
fusion. However, glycosphingolipids-deficient cells lines,
which were engineered to express HIV-1 receptors, were
highly susceptible to HIV-1 Env-mediated fusion [32] sug-
gesting little or no involvement of glycosphingolipids in
fusion of cells expressing high levels of HIV-1 receptors.
However, PPMP has a number of different effects on
sphingolipid metabolism, which include an increase of
ceramide levels [33,34]. Zimmerberg and co-workers per-
formed a very detailed study on the effects of PPMP-treat-
ment of cells on the membrane distribution of influenza
hemagglutinin [8]. Fluorescence spectroscopy indicated
that such treatment alters the relative distance and orien-
tation of these membrane-embedded proteins on molec-
ular scale (6–7 nm), and quantitative electron microscopy
indicated relatively small effects on longer (≥ 20 nm)
length scales. A similar study on CD4 and co-receptor dis-
tribution is beyond the scope of this study. However, CD4
has a similar domain structure as hemagglutinin (large
extracytoplasmic domain, one membrane-spanning
region, short cytoplasmic tail) and is also considered to be
Effect of PPMP Treatment on CD4 and Co-receptor Expression in NIH3T3 Cells Figure 3
Effect of PPMP Treatment on CD4 and Co-receptor Expression in NIH3T3 Cells. NIH3T3 target cells on 12 well 
plates (5 × 104 per well) were cultured in the presence of 10 μM PPMP for 48–72 hours. CD4, CXCR4 and CCR5 levels before 
and after treatment with PPMP were determined by FACS using PE-conjugated Mabs as described in materials and methods. 
The numbers in the boxes respresent means of the fluorescence histograms.
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Effect of PPMP treatment on HIV-18xV3BAL Env-mediated Fusion Figure 5
Effect of PPMP treatment on HIV-18xV3BAL Env-mediated Fusion. HIV-18xV3BAL Env mediated fusion with 
NIH3T3CCR5 (A) and NIH3T3CD4CCR5 (B) was monitored at different times with untreated (triangles) and PPMP-treated 
(squares) targets. PPMP treatment and fusion are described in the legends to Figures 3 and 2, respectively. The data were fit to 
the equation f = a/(1+exp(-(t-t1/2)/b)) using Sigmaplot (SPSS, Chicago), where a is the maximal extent, b represents the rate, 
and t1/2 is the time at which the half-maximal fusion extent is reached. The curve fitting yielded the following t1/2 values for 
untreated and PPMP-treated cells, respectively: 6.3 h and 10 h (A); 5.3 h and 10.5 h (B) The numbers above the data are p val-
ues determined by a paired student t test using Sigmaplot (SPSS, Chicago).
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Effect of PPMP treatment on HIV-18x Env-mediated Fusion Figure 4
Effect of PPMP treatment on HIV-18x Env-mediated Fusion. HIV-18x Env mediated fusion with NIH3T3CXCR4 (A) and 
NIH3T3CD4 CXCR4 (B) was monitored at different times with untreated (triangles) and PPMP-treated (squares) targets. 
PPMP treatment and fusion are described in the legends to Figures 3 and 2, respectively. The data were fit to the equation f = 
a/(1+exp(-(t-t1/2)/b)) using Sigmaplot (SPSS, Chicago), where a is the maximal extent, b represents the rate, and t1/2 is the time 
at which the half-maximal fusion extent is reached. The curve fitting yielded the following t1/2 values for untreated and PPMP-
treated cells, respectively: 7.1 h and 9.8 h (A); 4.6 h and 7.2 h (B). The numbers above the data are p values determined by a 
paired student t test using Sigmaplot (SPSS, Chicago).
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a "raft" protein [35]. We may therefore surmise that PPMP
treatment will exert a similar effect on CD4 distribution
on the cell surface. On the other hand, the seven trans-
membrane proteins CXCR4 and CCR5 may be less sensi-
tive to such treatment as indicated by the Ca2+ signaling
experiment (Figure 6). Therefore, the sensitivity to PPMP
treatment in the CD4-independent setting may be less
pronounced when a one-step mechanism is required to
mediate HIV-1 Env fusion.
Conclusion
By reducing HIV-1 Env-mediated fusion to a one-step
chemokine receptor- dependent process, we have shown
that cholesterol plays a role in both CD4 and chemokine
receptor-mediated steps, whereas modulation of sphin-
golipids only affects the choreography between the two
steps. Chemokine receptor function remained intact fol-
lowing treatment of cells with PPMP. Therefore such treat-
ment may be considered a more suitable agent to inhibit
CD4 dependent HIV-1 infection.
Methods
Materials
Phycoerythrin (PE)-labeled Mabs against CD4, CXCR4
and CCR5 and their isotype controls were obtained from
Pharmingen (San Diego, CA). The anti-GM3 Mab GMR6
was obtained from Seikagaku America (Falmouth, MA)
and Cy3-conjugated anti-mouse Fab from Jackson Immu-
nochemicals (West Grove, PA). Methyl-β-cyclodextrin
(MβCD) and cholesterol/MβCD complexes purchased
from Sigma (St. Louis, MI), and 1-phenyl-2-hexade-
canoylamino-3-morpholino-1-propanol (PPMP) from
Matreya, Inc. (Pleasant Gap, PA). Cholesterol in total cell
lysate was determined using the Cholesterol Oxidase kit
Chemokine-Triggered Ca2+ Mobilization Figure 6
Chemokine-Triggered Ca2+ Mobilization. Intracellular Ca2+ mobilization was measured by stimulating Fura-2 loaded 
NIH3T3CD4CXCR4 (A) or NIH3T3CD4CCR5 (B) cells with chemokines SDF1-α (A) or MIP1-β (B) at different concentra-
tions. The ratio of fluorescence at 340 and 380 nm was calculated using a FL Win Lab program (Perkin-Elmer). Left panel: 
untreated cells, middle panel: PPMP-treated cells; right panel: MβCD-treated cells.
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(Wako Chemicals USA Inc, Richmond, VA). The cytoplas-
mic dyes 5-chloromethylfluorescein diacetate (CMFDA),
5- and 6-([(4-chloromethyl)benzoyl]-amino)tetramethyl-
rhodamine (CMTMR) and Fura-2 AM were from Molecu-
lar Probes (Eugene, OR). The chemokine receptor ligands
SDF1-α and MIP1-β were from Peprotech (Rocky Hill,
NJ). All other biochemicals used were of the highest purity
available and were obtained from regular commercial
sources.
Cells and viruses
NIH 3T3 cells constitutively expressing CD4 and/or
CXCR4, and NIH 3T3 cells constitutively expressing CD4
and/or CCR5, were kindly provided by Dr. Dan Littman
(New York University, New York). HIV-1 Env 8x and
8xV3BAL [36], kindly provided by Dr. Robert Doms, Uni-
versity of Pennsylvania, Philadelphia, were expressed on
the surface of NIH3T3 cells by transfection using the vac-
cinia T7-polymerase (vTF7-3), which was obtained
through the AIDS Research and Reference Reagent Pro-
gram, Division of AIDS, NIAID, NIH from Drs Tom Fuerst
and Bernard Moss.
Surface expression of GM3, CD4 and chemokine receptors
The fluorescence of cells stained with PE-conjugated Mabs
against CD4, CXCR4 and CCR5 was compared with the
appropriate PE-conjugated isotype controls. Cell labeling
with PE-conjugated Mabs was done in the presence of 2%
serum, after which cells were washed and fixed with 1%
paraformaldehyde. The analysis was performed on a FAC-
Star plus flow cytometer. GM3 levels were monitored by
immunofluorescence using the anti-GM3 Mab (GMR6)
and a Cy5-stained antimouse Fab.
HIV-1 Env-mediated cell fusion
To express 8x or 8x-V3BaL gp120-gp41, NIH3T3 cells
plated on T75 flasks were incubated with the vaccinia
virus vTF7-3 (5 M.O.I.) for 1–2 hrs at 37°C. Subsequently,
the cells were transfected with 15 μg DNA (psp73.8x or
psp73.8x.V3BaL using lipofectamine (Invitrogen, Inc.) in
3 ml DMEM (without serum) and incubations were con-
tinued for 4–6 hrs at 37°C. DMEM containing 10% FBS +
antibiotics (D10) was added and cells were incubated for
additional 16–20 hours. For the fusion assay, cells were
harvested using EDTA-based cell dissociation buffer (Life
Technologies, Inc.) and labeled with 10 μM CMFDA fol-
lowing manufacturer's directions. The CMFDA-labeled
HIV-1 Env-expressing cells (2 × 105 per well) were added
to the same number of CMTMR-labeled NIH3T3 targets
expressing CD4 and/or cognate co-receptors and the sam-
ples were incubated for 4–10 hrs at 37°C. Dye redistribu-
tion as a result of fusion was monitored microscopically
as described previously [37]. The extent of fusion was cal-
culated as: Percent Fusion = 100 × number of cells positive
for both dyes/number of bound cells positive for CMTMR.
Calcium mobilization
Intracellular [Ca2+] mobilization was measured by incu-
bating 2 × 107 cells/ml in loading medium (DMEM con-
taining 10% FCS and 2 mM glutamine) with 7 mM Fura-
2 AM for 45 min at room temperature. The dye-loaded
cells were washed and resuspended in saline buffer (138
mM NaCl, 6 mM KCl, 1 mM CaCl2, 10 mM HEPES, 5 mM
glucose, and 0.1% BSA, pH 7.4) at a density of 0.5 × 106/
ml. The cells were then transferred into quartz cuvettes (1
× 106 cells in 2 ml saline buffer), which were placed in a
fluorescence spectrometer (Perkin-Elmer, Beaconsfield,
U. K.). Chemokines were added in a volume of 20 ml to
each cuvette. The intensity of the fluorescence was meas-
ured as the ratio at 340 and 380 nm wavelengths and cal-
culated using a FL WinLab program (Perkin-Elmer).
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